Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial Update investigating once-weekly PEG-somatropin (GenSci004) for safety and efficacy in children with growth hormone deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• PEG-somatropin (GenSci004) (pegylated somatropin)

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: GHD | Phase 3 | Status: UNKNOWN